Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
4.470
-0.380 (-7.84%)
At close: Jun 5, 2026, 4:00 PM EDT
4.450
-0.020 (-0.45%)
After-hours: Jun 5, 2026, 7:11 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 16 employees as of December 31, 2025. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$2,352,563
Market Cap
38.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 15 | 0 |
| Dec 31, 2023 | 12 | 1 | 9.09% | 12 | 0 |
| Dec 31, 2022 | 11 | 3 | 37.50% | 11 | 0 |
| Dec 31, 2021 | 8 | 0 | - | 6 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Plus Therapeutics | 28 |
| Tevogen Bio Holdings | 18 |
| RenovoRx | 17 |
| Nutriband | 13 |
| Actuate Therapeutics | 12 |
| Genenta Science | 9 |
| KALA BIO | 6 |
ATOS News
- 11 days ago - Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PRNewsWire
- 18 days ago - Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - PRNewsWire
- 19 days ago - Atossa Therapeutics Transcript: Status update - Transcripts
- 24 days ago - Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer - PRNewsWire
- 4 weeks ago - Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year - TheFly
- 4 weeks ago - Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PRNewsWire
- 4 weeks ago - Atossa Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Atossa Therapeutics Earnings release: Q1 2026 - Filings